Pfizer’s Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign-up to receive all GMG announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Care for Patients with HR+/HER2- or HER2+ (regardless of hormonal status) metastatic Breast Cancer (mBC)Release Date:Education Oncology Spain Research on Diagnostic and Treatment of Invasive Mold DiseaseRelease Date:Research Hospital China Research on Disease Burden of CRE (including non-MBL and MBL-CRE), CR-PA and Stenotrophomonas Maltophilia in ChinaRelease Date:Research Hospital China Educational approaches to address immunization practice gaps and improve adult vaccination coverage in SwitzerlandRelease Date:Education Vaccines Switzerland Improving Patient Care of Lower Respiratory Tract Infection Among InfantsRelease Date:Quality Improvement Vaccines Thailand China Medical Education in Non-small Cell Lung Cancer Diagnosis, Treatment and Long-Term Disease ManagementRelease Date:Education Oncology China Diagnosis and Treatment of Cancer CachexiaRelease Date:Education Oncology France, Germany, Italy, Japan, Spain, USA, United Kingdom Healthcare Optimization and Patient Equity for Lung Cancer in China (“HOPE”)Release Date:Partner: The International Association for the Study of Lung Cancer (IASLC)Quality Improvement Oncology China Optimizing ER+ Metastatic Breast Cancer Treatment: incorporating emerging treatment options and biomarker testingEducation Oncology All Optimizing vaccination pathways among at-risk or immunocompromised adults and the elderly in ItalyRelease Date:Quality Improvement Vaccines Italy Expanding Access to Maternal Immunization Resources and Point-of-Care ToolsRelease Date:Education Vaccines USA Title Grant Type Focus Area Country Application Due Date Transition of Care in VTERelease Date:Anticoagulation Education - NVAF or VTERelease Date:Review Process:Achievement of Treat-to-Target in Rheumatoid ArthritisRelease Date:Improving Care of Chronic Pain- Physician Groups and Health SystemsRelease Date:Facilitation of the Diagnosis of Rheumatoid ArthritisRelease Date:Pfizer and NCCN: Metastatic Breast CancerRelease Date:Pediatric Immunization Series CompletionRelease Date:Pfizer and National Psoriasis Foundation (NPF): Plugging the Treatment Gap in Psoriasis and Psoriatic ArthritisRelease Date:Pfizer and International Atherosclerosis Society (IAS): Lipid Management in High-Risk PatientsRelease Date:Pfizer and American Academy of Dermatology (AAD): Patient Access to CareRelease Date:Narrowing the Time Gap between Onset of Symptoms and Treatment for Rheumatoid ArthritisRelease Date: